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Haemophilus ducreyi produces two outer membrane proteins, called DltA (H. ducreyi lectin A) and DsrA (H.
ducreyi serum resistance A), that contribute to the ability of the organism to evade complement-mediated
serum killing. In contrast to their isogenic parent strain, 35000HP, the DsrA mutant FX517 exhibits 0%
survival in 50% normal human serum and the DltA mutant FX533 exhibits 23% survival. Compared to
35000HP, FX517 does not cause pustule formation in human volunteers. To test whether DltA was required for
virulence in humans, seven volunteers were experimentally infected with 35000HP and FX533. Four subjects
were inoculated with fixed doses of 35000HP (101 CFU or 130 CFU) at three sites on one arm and escalating
doses of FX533 (range, 46 CFU to 915 CFU) at three sites on the other arm. Pustules only developed at
mutant-injected sites at doses nearly twofold higher than that of the parent, suggesting that FX533 was
partially attenuated. Three subjects were inoculated with similar doses of the parent (67 CFU) and mutant (104
CFU) at three sites. Pustules formed at five of nine parent sites and one of nine mutant sites. Overall, the
papule and pustule formation rates for 35000HP and FX533 were similar for the trial. However, for the five
subjects who received similar doses of the parent and mutant, pustules developed at 7 of 15 sites (46.7%; 95%
confidence interval [CI], 16.9% to 76.5%) inoculated with the parent and at 1 of 15 (6.7%; 95% CI, 0.1% to
18.4%) sites inoculated with the mutant (P  0.043). We concluded that the DltA mutant was attenuated in its
ability to cause disease at doses similar to that of the parent.
Haemophilus ducreyi is a gram-negative, unencapsulated
bacterium that causes the genital ulcer disease chancroid,
which is characterized by painful genital ulcers and inguinal
lymphadenitis. Chancroid is rare in the United States (9) but
remains prevalent in developing countries (32). Because chan-
croid facilitates the acquisition and transmission of human
immunodeficiency virus type 1 (13, 19, 24, 32), H. ducreyi
remains an important pathogen.
To study H. ducreyi pathogenesis in humans, we developed
an experimental infection model in which strain 35000HP and
its derivatives are inoculated into the skin of the upper arms of
healthy volunteers (27, 31). The bacteria are delivered by punc-
ture wounds made by the tines of an allergy testing device,
simulating abrasions that occur during intercourse, the pre-
sumed natural route of infection. In the model, papules form
within 24 h of inoculation and either evolve into pustules in 2
to 5 days or resolve spontaneously. Men and women form
papules at similar rates, but the odds ratio of men developing
pustules is 2.8-fold (95% confidence interval [CI], 1.6- to 5.0-
fold) higher than that of women (7; unpublished observations).
For an individual inoculated at multiple sites, a pustule may
develop at one site while another site resolves (4, 30). Out-
comes (pustule formation versus resolution) at multiple sites
within a subject tend to be similar, suggesting that there is a
host effect on susceptibility to disease progression (28). When
subjects are challenged twice, they tend to have the same
outcome as their first infection, confirming the existence of a
host effect (3, 28).
To test the role of putative virulence determinants in hu-
mans, isogenic mutant-parent comparison trials have been per-
formed with the strain 35000HP (HP, human-passaged) back-
ground (27). Volunteers are inoculated with multiple doses of
35000HP on one arm and mutant derivatives of 35000HP on
the other arm and serve as their own controls for gender and
host effects. To date, all 16 mutants tested in the human model
are able to initiate papule formation. Mutants have fallen into
the following two categories: those that cause pustules at doses
similar to that of the parent and those unable to form pustules
at doses up to 10-fold higher than that of the parent. Mutants
of the flp operon, the hemoglobin receptor gene (hgbA), the
peptidoglycan-associated lipoprotein gene (pal), the H. ducreyi
serum resistance protein gene (dsrA), large supernatant pro-
tein genes (lspA1 and lspA2), and a collagen binding protein
gene (ncaA) are each attenuated for pustule formation (2, 8,
12, 17, 29; R. A. Fulcher, L. E. Cole, D. M. Janowicz, K. L.
Toffer, K. R. Fortney, B. P. Katz, P. E. Orndorff, S. M. Spinola,
and T. H. Kawula, unpublished data).
Recently, Leduc et al. described a 22-kDa outer membrane
protein (OMP), DltA (H. ducreyi lectin A), that binds to fi-
bronectin and was present in seven different H. ducreyi strains
tested (20). DltA shares conserved domains with -ricin chains
and an R-type lectin and binds to lactose, GalNAc, and several
N-glycosylated glycoproteins (20). DltA also contributes to the
ability of the organism to evade complement-mediated serum
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killing. 35000HP is resistant to normal human serum (NHS) at
concentrations up to 50% (11, 14). In contrast to 35000HP, the
isogenic dsrA mutant FX517 exhibits 0% survival in 50% nor-
mal human serum, while the isogenic dltA mutant FX533 ex-
hibits 23% survival (20). A double dsrA dltA mutant, FX534, is
more susceptible to 10% NHS than FX517, confirming that
both proteins contribute to serum resistance (20). DsrA medi-
ates resistance to serum by abrogating binding of immunoglob-
ulin M (IgM) to the bacteria and preventing the initiation of
the classical complement cascade (1). How DltA contributes to
serum resistance is under investigation.
In experimental human infection, H. ducreyi colocalizes with
polymorphonuclear leukocytes, macrophages, collagen, and fi-
brin but does not colocalize with laminin or fibronectin (5).
The bactericidal activity of human serum likely plays an important
role in H. ducreyi pathogenesis, in that blood and plasma,
which contain fibrin, transude into the wounds. The isogenic
dsrA mutant FX517 does not cause pustules in human volun-
teers, presumably because it is killed by serum (8). The role of
DltA in the pathogenesis of chancroid is currently unknown.
Here we tested the ability of FX533 to cause disease in humans.
Comparison of 35000HP and FX533. 35000HP is a human-
passaged variant of strain 35000 and was reported previously
(4). FX533, which contains a kanamycin resistance cassette
inserted into the dltA locus, was constructed in the 35000HP
background as described previously (20). Both strains were
grown on chocolate agar plates supplemented with 1% Iso-
VitaleX and incubated at 35°C with 5% CO2 or in broth con-
sisting of proteose peptone, 50 g of hemin per ml, 1% Iso-
VitaleX, and 5% heat-inactivated fetal calf serum. Where
appropriate, the media were supplemented with kanamycin (30
g/ml).
To examine whether FX533 had phenotypes other than that
caused by the dltA mutation, FX533 was compared to the
dedicated 35000HP stock used to infect volunteers. The com-
parison included growth rates in broth and OMP and lipooli-
gosaccharide (LOS) profiles, as described previously (12).
35000HP and FX533 had similar generation times in broth
(data not shown). OMP and LOS from 35000HP and FX533
were analyzed by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis. The OMP and LOS profiles demonstrated no
differences between the parent and the mutant (data not
shown). By Coomassie blue staining, DltA is a low-abundance
lipoprotein, and these results are similar to those reported
previously (20).
Human inoculation experiments. Healthy adult male and
female volunteers over 18 years of age were recruited for the
study. Subjects gave informed consent for participation and for
human immunodeficiency virus (HIV) serology, in accordance
with the human experimentation guidelines of the U.S. De-
partment of Health and Human Services and the Institutional
Review Board of Indiana University-Purdue University of In-
dianapolis. The experimental challenge protocol, preparation
and inoculation of the bacteria, calculation of the estimated
delivered dose (EDD), and clinical observations were done
exactly as described previously (17, 29). When a papule was
present, the area of erythema was calculated by measuring the
greatest dimensions vertically and horizontally in millimeters
and then multiplying the two measurements. The areas were
measured and recorded by a physician who was blinded to the
identity of the inoculum used at each site. Subjects were ob-
served until they reached a clinical end point, defined as either
14 days after inoculation, development of a pustule that was
either painful or 6 mm in diameter, or resolution of infection
at all sites. Once a clinical end point was achieved, the code
was broken. Up to four sites with active disease (inoculated
with the parent or the mutant), if present, were biopsied with
punch forceps. The subjects were then treated with two doses
of oral ciprofloxacin as described previously (4, 31).
Nine healthy adults (six females and three males; age range,
23 to 68 years; mean age  standard deviation, 40  16 years)
volunteered for the study. One subject (275) failed to meet the
entry criteria, and one subject (279) withdrew prior to inocu-
lation. A total of seven subjects participated in the trial. Two
subjects (273 and 274) were inoculated in the first iteration,
two subjects (276 and 277) were inoculated in the second
iteration, and three subjects (278, 280, and 281) were inocu-
lated in the third iteration (Table 1).
An escalating dose-response study was initially used. In the
first iteration, we inoculated two subjects on one arm at three
sites with 35000HP, with an EDD of 101 CFU, and on the
other arm at three sites with FX533, with EDDs of 46, 92, and
183 CFU. Papules developed at six of six sites injected with the
parent strain (parent sites) and five of six sites injected with the
mutant (mutant sites) (Table 1). Two parent sites developed
pustules, while no mutant sites developed pustules (Table 1).
Since the mutant seemed impaired in the ability to cause pus-
tules, we infected an additional two subjects and increased the
dose of the mutant. For subjects 276 and 277, the EDDs of the
mutant strain were 229, 457, and 915 CFU and the EDD of the
parent strain was 130 CFU. All six parent sites and all six
TABLE 1. Response of patients to inoculation with















273 F 8 35000HP 3 1 2
FX533 3 0 3
274 M 6 35000HP 3 1 2
FX533 2 0 2
276 M 6 35000HP 3 2 1
FX533 3 3 0
277 F 8 35000HP 3 0 3
FX533 3 1 2
278 F 8 35000HP 3 0 3
FX533 2 1 1
280 F 7 35000HP 3 2 1
FX533 3 0 3
281 F 6 35000HP 3 3 0
FX533 3 0 3
a Volunteers 273 and 274 were inoculated in the first iteration; volunteers 276
and 277 were inoculated in the second iteration; and volunteers 278, 280, and 281
were inoculated in the third iteration.
b M, male; F, female.
c There were no papules as a final outcome for any of the patients.
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mutant sites developed papules (Table 1). Pustules developed
at all three mutant sites in subject 276 and at the mutant site
inoculated with the highest dose in subject 277 (Table 1).
The results of the first two iterations suggested that FX533
was partially attenuated in the ability to form pustules. In the
first iteration, at doses comparable to that of the parent, the
mutant was unable to cause pustules. In the second iteration,
the mutant caused pustules at doses nearly twofold higher or
more than that of the parent. To test whether FX533 was
partially attenuated, we inoculated the third group of subjects
(278, 280, and 281) with similar EDDs of both the parent and
mutant strains. The EDD of the parent was 67 CFU, and the
EDD of the mutant was 104 CFU. Papules formed at nine of
nine sites inoculated with the parent and at eight of nine sites
inoculated with the mutant (Table 1). Pustules formed at five
of nine sites inoculated with the parent and at one of nine sites
inoculated with the mutant (Table 1).
Comparisons of papule and pustule formation rates and
proportions of positive surface cultures between the two strains
were performed by using a logistic regression model with gen-
eralized estimating equations to account for the correlation
among sites within the same subject, as described previously
(29). The generalized estimating equation sandwich estimate
for the standard errors was used to calculate 95% confidence
intervals for these rates. The cumulative results for the three
iterations showed that papules developed at 95.2% (95% CI,
79.3% to 99.9%) of sites inoculated with 35000HP and at
90.5% (95% CI, 79.3% to 99.9%) of sites inoculated with
FX533 (P  0.55). The surface area of papule erythema at
each site 24 h after inoculation for mutant papules (mean, 17.4
mm2) was not significantly different from that for parent pap-
ules (mean, 24.8 mm2) (P  0.065). Overall, pustules formed at
9 of 21 (42.9%; 95% CI, 17.4% to 68.3%) sites inoculated with
35000HP and at 5 of 21 (23.8%; 95% CI, 0.1% to 49.3%) sites
inoculated with FX533 (P  0.31).
Five subjects (273, 274, 278, 280, and 281) were inoculated
with similar parent (75.0  17.2 CFU [mean  standard de-
viation]) and mutant (104.6  37.3 CFU) EDDs. For these five
subjects, papules formed at 14 of 15 sites (93.3%; 95% CI,
81.7% to 99.9%) inoculated with 35000HP and at 13 of 15 sites
(86.7%; 95% CI, 81.7% to 99.9%) inoculated with FX533 (P 
0.55). The mean papule surface area for sites inoculated with
the parent (25.1 mm2) was similar to that for sites inoculated
with the mutant (15.1 mm2) (P  0.15). Pustules formed at 7 of
15 sites inoculated with the parent (46.7%; 95% CI, 16.9% to
76.5%), in contrast to 1 of 15 sites inoculated with the mutant
(6.7%; 95% CI, 0.1% to 18.4%) (P  0.04). Thus, the mutant
was attenuated in the ability to cause disease at doses similar to
that of the parent.
Recovery and characterization of bacteria from human le-
sions. To confirm that the inocula were correct and that the
mutant had not lost the kanamycin resistance insertion during
infection, individual colonies from the inocula, surface cul-
tures, and biopsy specimens were picked, suspended in freez-
ing medium, and frozen in 96-well plates. The colonies were
scored for susceptibility to kanamycin on kanamycin-contain-
ing chocolate agar plates. If available, sufficient colonies (n 
30) from an individual specimen were scored so that there was
a 95% probability that 11% of the colonies would have the
incorrect phenotype (2).
Of the 21 sites inoculated with the parent, 8 (38%) yielded
at least one positive surface culture, while 1 of 21 (5%) mutant
sites yielded a positive culture (P  0.04). Our protocol only
permits biopsy of sites where disease is present at the end
point. For subjects 273, 274, 280, and 281, pustules formed only
at parent sites. One parent biopsy yielded 3.4  105 CFU; five
additional biopsies were processed for other purposes and
were not cultured. For subject 276, one mutant biopsy yielded
3.4  105 CFU and one parent biopsy yielded 1.5  102 CFU.
For subject 277, one mutant pustule was processed for histo-
pathology, which was identical to that reported previously for
parent pustules (22, 30, 31; data not shown). For subject 278,
one mutant pustule yielded 0 CFU.
For the three parent and three mutant broth cultures used to
prepare the inocula, all 141 parent colonies and all 144 mutant
colonies tested were phenotypically correct (the mutant was
kanamycin resistant [Kanr], and the parent was kanamycin
sensitive [Kans]). All colonies obtained from surface cultures
(n  245) and biopsy specimens (n  49) from parent sites
were phenotypically correct, as were all colonies obtained from
surface cultures (n  1) and biopsy specimens (n  47) from
mutant sites.
Conclusions. Serum resistance is an important feature in the
pathogenesis of H. ducreyi infection (1, 8, 11, 20). Our previous
results demonstrated that the serum-susceptible dsrA mutant
was highly attenuated in human volunteers and prompted our
present experiments with the dltA mutant, which is also sus-
ceptible to serum. Overall, FX533 formed papules and pus-
tules at rates similar to those for 35000HP. However, at doses
comparable to that of the parent, FX533 was impaired in the
ability to form pustules. Because FX533 led to pustule forma-
tion at sites inoculated with doses twofold higher or more than
those of the parent but not with comparable doses, we classi-
fied FX533 as partially attenuated. This is the seventh demon-
stration that a putative virulence factor of H. ducreyi facilitates
pustule formation in humans, and FX533 is the first partially
attenuated mutant described for 35000HP.
National and local biosafety committees have precluded our
testing of a mutant complemented in trans in human subjects
because of the possibility of horizontal transfer of a broad-
host-range plasmid encoding a virulence determinant to skin
flora. When FX533 was complemented with dltA in trans, its
survival in 50% serum was similar to that of 35000HP (20).
Thus, the partial attenuation of FX533 observed in the human
model is very likely due to the lack of expression of DltA and
not to a secondary mutation.
The bactericidal activity of NHS is an important component
of innate host defenses against many bacterial pathogens (16,
21, 23). The major determinant of serum resistance in H.
ducreyi is the outer membrane protein DsrA (11). DsrA is a
member of a family of outer membrane proteins that confer
resistance to killing and prevent binding of IgM and comple-
ment to the bacterial surface (1, 15, 25). The dsrA mutant
FX517 was unable to form pustules in human volunteers (8).
Compared to FX517, FX533 demonstrates partial serum sus-
ceptibility (20), consistent with its partial attenuation for pus-
tule formation in human volunteers. The serum resistance of
35000HP is also mediated in part by the major OMP (MOMP)
(14), an OmpA homologue, which in other organisms also
plays a role in serum resistance. A MOMP mutant was not
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attenuated for pustule formation in human volunteers, perhaps
because 35000HP expresses a second OmpA homologue,
OmpA2 (18, 33).
DltA confers the ability of 35000HP to attach to fibronectin.
DltA is affinity purified on lactose and N-acetylglucosamine,
and N-glycosylated glycoproteins bind to DltA in ligand blots
(20). DsrA mediates attachment to keratinocytes (10). How-
ever, confocal microscopy on experimental lesions failed to
demonstrate 35000HP binding to fibronectin or keratinocytes
(6). Throughout the course of experimental infection, 35000HP
colocalizes with collagen, fibrin, macrophages, and polymor-
phonuclear cells in the upper dermis (5, 6, 27). We did not
perform localization studies with FX533-infected pustules due
to the paucity of samples. Lectins play important roles as
adhesion molecules between bacteria and host cells during
infection (26). DltA may recognize glycosylated receptors on
host cells and play a role in the adhesion of H. ducreyi to host
tissues.
In summary, these data show that the loss of expression of
DltA results in partial attenuation of 35000HP. The mecha-
nism by which DltA confers virulence, whether through serum
resistance or attachment to lactose-related carbohydrates on
host cell membranes, is unclear. Studies are ongoing to delin-
eate how DltA affects virulence.
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